SOHO State of the Art Updates and Next Questions: Is Favorable-risk AML Always Favorable?
- Author(s)
- Tedjaseputra, A; Russell, N; Dillon, R;
- Details
- Publication Year 2026-06,Volume 26,Issue #6,Page e723-e729
- Journal Title
- Clinical Lymphoma, Myeloma & Leukemia
- Publication Type
- Review
- Abstract
- The 2022 European LeukaemiaNet acute myeloid leukemia (AML) classification allocates AML with t(8;21) RUNX1::RUNX1T1 fusion and AML with inv(16) or t(16;16) CBFB::MYH11 fusion (collectively, core-binding factor AML), AML with NPM1 without FLT3-ITD mutation and AML with CEBPA bZIP in-frame mutation into the favorable-risk strata based on initial molecular diagnostics. Generally, these entities have a relatively low risk of relapse (< 30%-40%) and many patients (> 50%-60%) survive long-term with intensive chemotherapy alone. However, there is growing literature that patterns of co-mutation, and more importantly, postremission measurable residual disease (MRD) status, modify these risks dynamically; necessitating an adaptive approach to optimize patient outcomes. In this review, we summarize evidence on how molecular and MRD features could assist clinicians in identifying high-risk patients within these favorable-risk subgroups, and where escalation of therapy, including with allogeneic transplantation in first remission, may be beneficial.
- Publisher
- Elsevier
- Keywords
- Humans; *Leukemia, Myeloid, Acute/genetics/therapy/diagnosis; Nucleophosmin; Neoplasm, Residual; Cbfb::Myh11; Cebpa; Npm1; Runx1::Runx1t1; inv(16); t(8; 21)
- Department(s)
- Haematology
- Publisher's Version
- https://doi.org/10.1016/j.clml.2026.03.013
- Open Access at Publisher's Site
https://doi.org/10.1016/j.clml.2026.03.013- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-05-05 06:05:43
Last Modified: 2026-06-23 03:42:08